Terry Rosen compensation by year
Arcus Biosciences Summary Compensation Table · all 9 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Salary | $314,780 | $295,000 | $340,000 | $325,625 | $366,875 | $350,000 | $650,000 | $725,000 | $775,000 |
| Bonus | $0 | $0 | $0 | $0 | $300,000 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $3,005,000 | $1,652,850 | $2,146,950 | $2,327,514 | $1,544,000 | $2,199,450 |
| Option awards | $110,775 | $828,279 | $1,375,700 | $2,351,475 | $6,896,008 | $6,145,370 | $6,582,319 | $4,380,960 | $6,008,860 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $0 | $400,000 | $550,000 | $615,000 | $658,750 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $1,200 | $1,650 | $1,200 | $1,200 | $265,241 | $6,112 | $11,112 | $14,544 | $14,753 |
| Total | $426,755 | $1,124,929 | $1,716,900 | $5,683,300 | $9,480,974 | $9,048,432 | $10,120,945 | $7,279,504 | $9,656,813 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Arcus Biosciences, Inc. DEF 14A filed April 21, 2026, accession 0001724521-26-000025, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Arcus Biosciences, Inc. filed document, accession 0001724521-26-000025. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 123,750 | $2,948,963 | — |
| RSU | 50,000 | $1,191,500 | — |
| RSU | 26,425 | $629,708 | — |
| Option | 4,255 | — | $33.03 |
| Option | 501,042 | — | $13.33 |
| Option | 116,187 | — | $22.02 |
| Option | 211,406 | — | $15.44 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Arcus Biosciences, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Arcus Biosciences’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Terry Rosen · this page | Chief Executive Officer and Director | $9,656,813 |
| Richard Markus | Chief Medical Officer | $4,506,299 |
| Juan Carlos Jaen | President | $3,520,924 |
| Jennifer Jarrett | Chief Operating Officer | $3,516,199 |
| Robert Goeltz | Chief Financial Officer | $2,672,564 |
Board service
Arcus Biosciences board · FY2021–FY2025How this board is paid
Company policy: Arcus Biosciences pays directors a $45,000 cash retainer and $400,000 in equity. As stated in Arcus Biosciences's FY2025 proxy.
The full Arcus Biosciences compensation record
free company briefThis page is one person within Arcus Biosciences's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Arcus Biosciences proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Arcus Biosciences's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Arcus Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order RCUS
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.